Repligen Corporation $RGEN Stock Position Decreased by UBS Group AG

Key Points

• UBS trimmed its stake in Repligen by 23.8% in Q4, selling 108,541 shares and leaving it with 348,388 shares (about 0.62% of the company) valued at roughly $57.09 million.
• Q1 beat and guidance: Repligen reported $0.48 EPS vs. $0.38 expected and $194.3M revenue, set FY‑2026 EPS guidance of $1.97–$2.05 and plans a ~1 percentage‑point operating margin lift by end‑2027; however, its revenue guidance of $803M–$833M may be lower than some Street estimates.
• Analyst sentiment is mixed but tilted positive, with an average rating of "Moderate Buy" and an average target price of $168.75 amid both upgrades and downgrades from brokers.

UBS Group AG lessened its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 348,388 shares of the biotechnology company's stock after selling 108,541 shares during the period. UBS Group AG owned 0.62% of Repligen worth $57,087,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of RGEN. AQR Capital Management LLC bought a new stake in shares of Repligen during the 1st quarter valued at about $262,000. Jones Financial Companies Lllp increased its position in Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after buying an additional 6,238 shares during the period. Goldman Sachs Group Inc. increased its position in Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after buying an additional 20,375 shares during the period. Bank of Nova Scotia increased its position in Repligen by 88.0% in the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company's stock worth $3,951,000 after buying an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company's stock worth $3,880,000 after buying an additional 7,148 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Price Performance

NASDAQ RGEN opened at $125.61 on Wednesday. Repligen Corporation has a 52 week low of $109.50 and a 52 week high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of 147.78, a price-to-earnings-growth ratio of 2.30 and a beta of 1.09. The company has a 50-day moving average price of $121.36 and a two-hundred day moving average price of $144.51.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same period in the prior year, the business posted $0.39 EPS. The business's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts forecast that Repligen Corporation will post 1.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RGEN. UBS Group dropped their target price on Repligen from $200.00 to $195.00 and set a "buy" rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Wells Fargo & Company decreased their target price on shares of Repligen from $190.00 to $180.00 and set an "overweight" rating for the company in a research report on Wednesday, February 25th. Weiss Ratings cut shares of Repligen from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, March 3rd. Finally, HC Wainwright upped their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, March 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $168.75.

Key Headlines Impacting Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q1 beat on EPS and revenue — Repligen reported Q1 EPS of $0.48 vs. consensus $0.38 and revenue of ~$194.3M vs. ~$192.1M, with revenue up ~14.8% year‑over‑year; the beat supports near‑term growth expectations. Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
• Positive Sentiment: FY‑2026 EPS guidance and margin plan — Repligen set FY‑2026 EPS of $1.97–$2.05 (in line with consensus) and announced a target to lift operating margins by ~1 percentage point by end‑2027, signaling management is focused on improving profitability. Repligen forecasts $1.97-$2.05 EPS on $803M-$833M 2026 revenue, as it targets 1 point margin lift by end of 2027
• Positive Sentiment: Strategic reshaping and China positioning — Coverage highlights management actions to reshape operations and adjust China reach; investors may view this as proactive cost/control and growth positioning that could support valuation upside. Repligen Reshapes Operations And China Reach As Valuation Signals Upside
• Neutral Sentiment: Earnings call details available — Full Q1 earnings call/transcript provides management color on demand trends, product lines and execution; useful for assessing sustainability of the beat. Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Street coverage and summaries — Multiple outlets summarized the results and reaction (MSN, Stamford Advocate, Zacks), helpful for cross‑checking analyst takeaways. Repligen (RGEN) shares skyrocket, what you need to know
• Negative Sentiment: Revenue guidance ambiguity — FY‑2026 revenue guidance of $803M–$833M sits below some Street point estimates (consensus ~ $827.9M), which could cap upside if execution misses the midpoint. Investors should watch quarterly cadence vs. guidance. Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.